Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
旧金山，2024 年 3 月 22 日 /PRNewswire/ — Nektar Therapeutics（纳斯达克股票代码：NKTR）管理层计划出席即将到来的 H.C. Wainwright 2和 年度自身免疫和炎症性疾病虚拟会议将于 2024 年 3 月 28 日星期四美国东部时间下午 1:30 /太平洋时间上午 10:30 举行。
The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until April 28, 2024.
演示和问答环节将通过Nektar网站 “投资者活动” 部分发布的链接通过网络直播观看： https://ir.nektar.com/events-and-presentations/events。该网络直播将在2024年4月28日之前重播。
About Nektar Therapeutics
关于 Nektar Therapeu
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Other pipeline programs include two preclinical candidates, a PEG-colony stimulating factor protein engineered to selectively modulate resolution processes of inflammation and NKTR-0165, a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Nektar Therapeutics是一家处于临床阶段的生物技术公司，专注于开发治疗自身免疫和慢性炎症性疾病中潜在免疫功能障碍的治疗方法。Nektar的主要候选产品rezpegaldesleukin（REZPEG，或 NKTR-358）是一种新型、同类首创的调节性T细胞刺激剂，正在两项2b期临床试验中进行评估，一项针对特应性皮炎，另一项用于斑秃症。其他研发项目包括两种临床前候选药物，一种专为选择性调节炎症消退过程而设计的 PEG-colony 刺激因子蛋白，以及 NKTR-0165，一种双价肿瘤坏死因子受体 II 型激动剂抗体。Nektar 还与多家合作伙伴一起在多项正在进行的临床试验中评估 NKTR-255，这是一种在研的 IL-15 受体激动剂，旨在增强免疫系统对抗癌症的自然能力。Nektar 总部位于加利福尼亚州旧金山。欲了解更多信息，请访问 www.nektar.com 并在领英上关注我们。
Contact:
联系人：
For Investors:
对于投资者：
Vivian Wu of Nektar Therapeutics
628-895-0661
Nektar Therapeutics 的吴薇安
628-895-0661
For Media:
对于媒体：
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
Argot Partners 的大卫罗森
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-the-hc-wainwright-2nd-annual-autoimmune--inflammatory-disease-virtual-conference-302097317.html
SOURCE Nektar Therapeutics
来源 Nektar Therapeut